727 filings
Page 2 of 37
SC 13D/A
usf ib8j49
12 Feb 24
KINETA / Iadonato Shawn ownership change
4:05pm
SC 13G/A
pl2ro 7rqo4
12 Feb 24
KINETA / Magness Charles ownership change
4:05pm
8-K
fw65grojoud 59nh
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
26e1h3bqe6ahv xwm2my
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
2s6sanalcfl x3amp
15 Dec 23
Entry into a Material Definitive Agreement
8:30am
4
r7s zzpwv
6 Dec 23
KINETA / Raymond J. Bartoszek ownership change
6:21pm
4
aag1l28uifso 8aj3a
30 Nov 23
KINETA / CRAIG W. PHILIPS ownership change
5:27pm
4
43nao466am 83zuh17r
30 Nov 23
KINETA / Shawn Iadonato ownership change
5:21pm
EFFECT
4swvu2c vo4az2
15 Nov 23
Notice of effectiveness
12:15am
424B3
p2wy5e6bjg
13 Nov 23
Prospectus supplement
5:28pm
UPLOAD
a7g vmh54y3n1ssju
9 Nov 23
Letter from SEC
12:00am
CORRESP
sohuqs649hj9ge0604
9 Nov 23
Correspondence with SEC
12:00am
8-K
1oe 0rbt804pz2jzl
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
vphom
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
io6aftx0dpdzllgum0i
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
D
q4n2c6jsvyh mrt
20 Oct 23
$2.89 mm in options / securities to be acquired, 1 investor
1:04pm
8-K
qtkw65ust5lll7s9is
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
4
d0ci544 lhw
12 Oct 23
KINETA / Marion R Foote ownership change
4:25pm